Venous and arterial thromboembolic complications associated with HIV infection and highly active antiretroviral therapy

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 830-838

  Auerbach, Evan ^a   Aboulafia, David M ^a,b  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

drug interactions; HAART; HIV AIDS; myocardial infarction; thrombosis

Indexed keywords

ABACAVIR; ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; ANTITHROMBIN III; ATAZANAVIR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; D DIMER; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FIBRINOGEN; HEPARIN COFACTOR II; HOMOCYSTEINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VON WILLEBRAND FACTOR; WARFARIN; ZIDOVUDINE;

ACUTE HEART INFARCTION; AIDS PATIENT; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DRUG CLASSIFICATION; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; GENE MUTATION; GROUPS BY AGE; HEMOPHILIA; HEPARIN INDUCED THROMBOCYTOPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE; LIVER FAILURE; LIVER HYPERTROPHY; LUNG EMBOLISM; META ANALYSIS (TOPIC); OPPORTUNISTIC INFECTION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84868562602     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328887     Document Type: Article

References (78)

1. Thompson M. A., Aberg J. A., Cahn P., et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: 2010; 304 3 321 333
2. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://www.aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 17, 2012
3. Sterne J. A., Hernán M. A., Ledergerber B., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet: 2005; 366 9483 378 384 (Pubitemid 41073955)
4. Walensky R. P., Paltiel A. D., Losina E., et al. The survival benefits of AIDS treatment in the United States. J Infect Dis: 2006; 194 1 11 19
5. Aboulafia D. An update on HIV-associated venous thromboembolism in the era of highly active antiretroviral therapy. J Coagul Disord: 2010; 2 49 56
6. Crum-Cianflone N. F., Weekes J., Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS: 2008; 22 10 771 778
7. Eyal A., Veller M. HIV and venous thrombotic events. S Afr J Surg: 2009; 47 2 54 56
8. Cruciani M., Zanichelli V., Spelloni G., et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS: 2011; 25 1993 2004
9. Bozzette S. A., Ake C. F., Tam H. K., Chang S. W., Louis T. A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med: 2003; 348 8 702 710 (Pubitemid 36237039)
10. Vispo E., Moreno A., Maida I., et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS: 2010; 24 8 1171 1176
11. Mallet V. O., Varthaman A., Lasne D., et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS: 2009; 23 12 1511 1518
12. Kovari H., Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS: 2011; 6 4 272 277
13. World Health Organization Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva, Switzerland World Health Organization: 2011
14. Klein S. K., Slim E. J., de Kruif M. D., et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med: 2005; 63 4 129 136 (Pubitemid 40561527)
15. Sullivan P. S., Dworkin M. S., Jones J. L., Hooper W. C. Epidemiology of thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project. AIDS: 2000; 14 3 321 324 (Pubitemid 30132927)
16. Fultz S. L., McGinnis K. A., Skanderson M., Ragni M. V., Justice A. C. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med: 2004; 116 6 420 423 (Pubitemid 38299488)
17. Saber A. A., Aboolian A., LaRaja R. D., Baron H., Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg: 2001; 67 7 645 647 (Pubitemid 33739079)
18. Malek J., Rogers R., Kufera J., Hirshon J. M. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med: 2011; 29 3 278 282
19. Copur A. S., Smith P. R., Gomez V., Bergman M., Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS: 2002; 16 5 205 209 (Pubitemid 34478160)
20. Saif M. W., Bona R., Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS: 2001; 15 6 311 320 (Pubitemid 32554157)
21. Jenkins R. E., Peters B. S., Pinching A. J. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS: 1991; 5 12 1540 1542
22. Hassell K. L., Kressin D. C., Neumann A., Ellison R., Marlar R. A. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coagul Fibrinolysis: 1994; 5 4 455 462 (Pubitemid 24301563)
23. Laing R. B., Brettle R. P., Leen C. L. Venous thrombosis in HIV infection. Int J STD AIDS: 1996; 7 2 82 85 (Pubitemid 26128283)
24. George S. L., Swindells S., Knudson R., Stapleton J. T. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med: 1999; 107 6 624 630
25. Howling S. J., Shaw P. J., Miller R. F. Acute pulmonary embolism in patients with HIV disease. Sex Transm Infect: 1999; 75 1 25 29 (Pubitemid 29117477)
26. Matta F., Yaekoub A. Y., Stein P. D. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci: 2008; 336 5 402 406
27. Rasmussen L. D., Dybdal M., Gerstoft J., et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med: 2011; 12 4 202 210
28. Ahonkhai A. A., Gebo K. A., Streiff M. B., Moore R. D., Segal J. B. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr: 2008; 48 3 310 314
29. Louw S., Jacobson B. F., Büller H. Human immunodeficiency virus infection and acute deep vein thromboses. Clin Appl Thromb Hemost: 2008; 14 3 352 355 (Pubitemid 351871937)
30. Jansen J. M., Lijfering W. M., Sprenger H. G., van der Meer J., van Pampus M. G. Venous thromboembolism in HIV-positive women during puerperium: a case series. Blood Coagul Fibrinolysis: 2008; 19 1 95 97
31. Nagaraja V., Terriquez J. A., Gavini H., Jha L., Klotz S. A. Pulmonary embolism mimicking pneumonia in a HIV patient. Case Report Med: 2010; June14: 10.1155/2010/394546 [Epub ahead of print]
32. Jacobson M. C., Dezube B. J., Aboulafia D. M. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis: 2004; 39 8 1214 1222 (Pubitemid 40169322)
33. Jong E., Louw S., Meijers J. C., et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS: 2009; 23 12 1001 1007
34. Kiser K. L., Badowski M. E. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy: 2010; 30 12 1292 1302
35. Baker J. V., Lundgren J. D. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J: 2011; 32 8 945 951
36. Funderburg N. T., Mayne E., Sieg S. F., et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood: 2010; 115 2 161 167
37. Musselwhite L. W., Sheikh V., Norton T. D., et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS: 2011; 25 6 787 795
38. Koppel K., Bratt G., Schulman S., Bylund H., Sandström E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr: 2002; 29 5 441 449 (Pubitemid 34456334)
39. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS: 1998; 12 7 F51 F58 (Pubitemid 28190689)
40. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS: 2003; 17 01 S141 S148 (Pubitemid 36667790)
41. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med: 2005; 352 1 48 62 (Pubitemid 40075680)
42. Barbaro G. Heart and HAART: two sides of the coin for HIV-associated cardiology issues. World J Cardiol: 2010; 2 3 53 57
43. Calmy A., Gayet-Ageron A., Montecucco F., et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS: 2009; 23 8 929 939
44. Rosendaal F. R. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost: 1997; 78 1 1 6 (Pubitemid 27289208)
45. Torriani F. J., Komarow L., Parker R. A., et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J Am Coll Cardiol: 2008; 52 7 569 576
46. Chai H., Yang H., Yan S., et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr: 2005; 40 1 12 19 (Pubitemid 41233198)
47. Friis-Moller N., Reiss P., Sabin C. A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med: 2007; 356 17 1723 1735 (Pubitemid 46658704)
48. Dubé M. P., Lipshultz S. E., Fichtenbaum C. J., et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation: 2008; 118 2 e36 e40
49. Durand M., Sheehy O., Baril J. G., Lelorier J., Tremblay C. L. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr: 2011; 57 3 245 253
50. Obel N., Farkas D. K., Kronborg G., et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med: 2010; 11 2 130 136
51. Sabin C. A., Worm S. W., Weber R., et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet: 2008; 371 9622 1417 1426
52. Podzamczer D., Ferrer E., Sanchez P., et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr: 2007; 44 2 139 147 (Pubitemid 46292215)
53. Fätkenheuer G., Duvivier C., Rieger A., et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother: 2012; 67 3 685 690
54. Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS: 2008; 22 14 F17 F24
55. Lang S., Mary-Krause M., Cotte L., et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med: 2010; 170 14 1228 1238
56. Bedimo R. J., Westfall A. O., Drechsler H., Vidiella G., Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis: 2011; 53 1 84 91
57. Brothers C. H., Hernandez J. E., Cutrell A. G., et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr: 2009; 51 1 20 28
58. Padilla S., Masiá M., García N., Jarrin I., Tormo C., Gutiérrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis: 2011; 11 40
59. Ding X., Andraca-Carrera E., Cooper C., et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections 2011;paper #808.
60. European AIDS Clinical Society EACS HIV guidelines. PARIS, France: European AIDS Clinical Society; 2011. Available at: http://www. europeanaidsclinicalsociety.org. Accessed September 17, 2012
61. Behrens G. M. Abacavir and myocardial infarctions: the benefit of doubt? AIDS: 2011; 25 16 2043 2045
62. Maida I., Garcia-Gasco P., Sotgiu G., et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther: 2008; 13 1 103 107 (Pubitemid 351541679)
63. Bihl F., Janssens F., Boehlen F., Rubbia-Brandt L., Hadengue A., Spahr L. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol: 2010; 10 6
64. Scourfield A., Waters L., Holmes P., et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS: 2011; 22 6 324 328
65. Mendizabal M., Craviotto S., Chen T., Silva M. O., Reddy K. R. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol: 2009; 8 4 390 395
66. Soriano V., Puoti M., Garcia-Gascó P., et al. Antiretroviral drugs and liver injury. AIDS: 2008; 22 1 1 13 (Pubitemid 350301936)
67. Fihn S. D., McDonell M., Martin D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med: 1993; 118 7 511 520 (Pubitemid 23085793)
68. Goldstein K., Gluckman S., Mounzer K. Challenge of co-administering antiretroviral therapy and oral anticoagulants in HIV-positive patients. AIDS Read: 2008; 18 9 480 482, 486-489
69. Welzen M. E., van den Berk G. E., Hamers R. L., Burger D. M. Interaction between antiretroviral drugs and acenocoumarol. Antivir Ther: 2011; 16 2 249 252
70. Holbrook A. M., Pereira J. A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med: 2005; 165 10 1095 1106 (Pubitemid 40720733)
71. Liedtke M. D., Rathbun R. C. Warfarin-antiretroviral interactions. Ann Pharmacother: 2009; 43 2 322 328
72. Thompson G. R. III, Lawrence V. A., Crawford G. E. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin Infect Dis: 2007; 45 10 1393 1396 (Pubitemid 351411920)
73. Racoosin J. A., Kessler C. M. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia: 1999; 5 4 266 269 (Pubitemid 29445752)
74. Pollmann H., Richter H., Jürgens H. Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors. Thromb Haemost: 1998; 79 6 1213 1214 (Pubitemid 28297173)
75. Graff J., von Hentig N., Kuczka K., et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother: 2008; 61 2 394 399
76. Becattini C., Agnelli G., Schenone A., et al. WARFASA Investigators Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med: 2012; 366 21 1959 1967
77. Uchino K., Hernandez A. V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med: 2012; 172 5 397 402
78. Hsue P. Y., Scherzer R., Grunfeld C., et al. HIV infection is associated with decreased thrombin generation. Clin Infect Dis: 2012; 54 8 1196 1203